NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name (Descending) | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
52125-0709-02 | 52125-0709 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Sept. 19, 2013 | April 5, 2016 | No Longer Used |
62559-0890-30 | 62559-0890 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Oct. 26, 2020 | In Use | |
69189-0298-01 | 69189-0298 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | March 1, 2015 | May 24, 2017 | No Longer Used |
00093-0220-01 | 00093-0220 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | July 6, 2009 | Oct. 31, 2019 | No Longer Used |
00093-0220-56 | 00093-0220 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | July 6, 2009 | Oct. 31, 2019 | No Longer Used |
16714-0571-01 | 16714-0571 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Aug. 28, 2009 | Sept. 30, 2019 | In Use |
16714-0571-02 | 16714-0571 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Aug. 28, 2009 | Sept. 30, 2019 | In Use |
16714-0571-03 | 16714-0571 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Aug. 28, 2009 | Sept. 30, 2019 | In Use |
42291-0168-30 | 42291-0168 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Jan. 13, 2014 | Sept. 17, 2018 | No Longer Used |
42291-0168-50 | 42291-0168 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Jan. 13, 2014 | Sept. 17, 2018 | No Longer Used |
65841-0613-01 | 65841-0613 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | July 6, 2009 | In Use | |
65841-0613-05 | 65841-0613 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | July 6, 2009 | In Use | |
65841-0613-06 | 65841-0613 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | July 6, 2009 | In Use | |
65841-0613-10 | 65841-0613 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | July 6, 2009 | In Use | |
65841-0613-30 | 65841-0613 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | July 6, 2009 | In Use | |
68382-0224-01 | 68382-0224 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | July 6, 2009 | In Use | |
68382-0224-05 | 68382-0224 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | July 6, 2009 | In Use | |
68382-0224-06 | 68382-0224 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | July 6, 2009 | In Use | |
68382-0224-10 | 68382-0224 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | July 6, 2009 | In Use | |
68382-0224-30 | 68382-0224 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | July 6, 2009 | In Use | |
68382-0224-77 | 68382-0224 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | July 6, 2009 | In Use | |
70518-2993-00 | 70518-2993 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Jan. 15, 2021 | In Use | |
00015-3012-60 | 00015-3012 | Carmustine | BiCNU | Chemotherapy | Alkylating Agent | Nitrosourea | Intravenous | June 1, 2009 | Sept. 30, 2015 | No Longer Used | |
23155-0261-41 | 23155-0261 | Carmustine | BiCNU | Chemotherapy | Alkylating Agent | Nitrosourea | April 4, 2013 | In Use | |||
00007-3262-01 | 00007-3262 | Tositumomab, Iodine I-131 | Bexxar Therapeutic | Immunotherapy | Radioimmunotherapy | CD20 | July 15, 2009 | Feb. 20, 2014 | No Longer Used | ||
00007-3261-01 | 00007-3261 | Tositumomab, Iodine I-131 | Bexxar Dosimetric | Immunotherapy | Radioimmunotherapy | CD20 | July 15, 2009 | Feb. 13, 2014 | No Longer Used | ||
00007-3260-31 | 00007-3260 | Tositumomab | Bexxar | Immunotherapy | Radioimmunotherapy | CD20 | July 15, 2009 | Nov. 28, 2014 | No Longer Used | ||
00007-3260-36 | 00007-3260 | Tositumomab | Bexxar | Immunotherapy | Radioimmunotherapy | CD20 | July 15, 2009 | Nov. 28, 2014 | No Longer Used | ||
00378-6955-01 | 00378-6955 | Bexarotene | Bexarotene | 75.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | July 9, 2015 | In Use | |
68682-0003-10 | 68682-0003 | Bexarotene | Bexarotene | 75.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Dec. 17, 2015 | In Use | |
43975-0315-10 | 43975-0315 | Bexarotene | Bexarotene | 75.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | May 10, 2018 | In Use | |
00832-0285-00 | 00832-0285 | Bexarotene | Bexarotene | 75.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | July 25, 2018 | In Use | |
69238-1250-01 | 69238-1250 | Bexarotene | Bexarotene | 75.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Sept. 4, 2018 | In Use | |
00054-0399-25 | 00054-0399 | Bexarotene | Bexarotene | 75.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Nov. 11, 2020 | In Use | |
00591-2832-01 | 00591-2832 | Bexarotene | Bexarotene | 75.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Nov. 11, 2021 | In Use | |
42292-0007-01 | 42292-0007 | Bexarotene | Bexarotene | 75.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | April 15, 2016 | Jan. 31, 2020 | No Longer Used |
42292-0007-10 | 42292-0007 | Bexarotene | Bexarotene | 75.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | April 15, 2016 | Jan. 31, 2020 | No Longer Used |
68682-0002-60 | 68682-0002 | Bexarotene | Bexarotene | 1.0 g/100g | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Topical | June 28, 2000 | In Use | |
69238-2088-06 | 69238-2088 | Bexarotene | Bexarotene | 10.0 mg/g | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Topical | May 4, 2022 | In Use | |
42291-0072-01 | 42291-0072 | Bexarotene | Bexarotene | 75.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | April 14, 2023 | In Use | |
00008-0100-01 | 00008-0100 | Inotuzumab Ozogamicin | Besponsa | 0.25 mg/mL | Immunotherapy | Drug Antibody Conjugate | CD22 | Intravenous | Aug. 18, 2017 | In Use | |
63459-0348-04 | 63459-0348 | Bendamustine Hydrochloride | Bendeka | 25.0 mg/mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Dec. 8, 2015 | In Use | |
16729-0250-03 | 16729-0250 | Bendamustine hydrochloride | Bendamustine hydrochloride | 25.0 mg/5mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Dec. 7, 2022 | In Use | |
16729-0251-05 | 16729-0251 | Bendamustine hydrochloride | Bendamustine hydrochloride | 100.0 mg/20mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Dec. 7, 2022 | In Use | |
68001-0571-41 | 68001-0571 | Bendamustine hydrochloride | Bendamustine hydrochloride | 25.0 mg/5mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Feb. 22, 2023 | In Use | |
68001-0572-41 | 68001-0572 | Bendamustine hydrochloride | Bendamustine hydrochloride | 100.0 mg/20mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Feb. 22, 2023 | In Use | |
67457-0325-12 | 67457-0325 | Bendamustine Hydrochloride | Bendamustine Hydrochloride | 25.0 mg/5mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | April 26, 2018 | Feb. 21, 2019 | In Use |
67457-0326-05 | 67457-0326 | Bendamustine Hydrochloride | Bendamustine Hydrochloride | 100.0 mg/20mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | April 26, 2018 | Feb. 21, 2019 | In Use |
60505-6228-00 | 60505-6228 | Bendamustine Hydrochloride | Bendamustine Hydrochloride | 25.0 mg/mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | April 26, 2023 | In Use | |
68152-0108-09 | 68152-0108 | Belinostat | Beleodaq | 500.0 mg/10mL | Chemotherapy | Enzyme Inhibitor | HDAC | Intravenous | July 21, 2014 | Nov. 30, 2022 | In Use |
Found 10,000 results in 6 milliseconds — Export these results